Mark Goldberg was appointed a member of the Company’s Board in January 2014. He served as a director of Synageva Biophamra from 2008-2011, stepping down to become a member of the executive management team from 2011-2014, rising to Executive Vice President, Medical and Regulatory Strategy during a portion of 2014. In late 2014 he stepped down from the executive management team and continued to be employed part-time, contributing to medical and regulatory strategy until leaving upon the acquisition by Alexion. Before joining the management team at Synageva he served in various management capacities of increasing responsibility at Genzyme Corporation from 1996 to 2011, most recently as Senior Vice President for Clinical Development and Global Therapeutic Group Head for Oncology and Personalized Genetic Health. He was also the Chairman of Genzyme’s Early Product Review Board. While at Genzyme, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme®, Aldurazyme®, Myozyme® and Lumizyme®. Prior to joining Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Institute, where he still holds appointments. Dr. Goldberg is a part-time Associate Professor of Medicine at Harvard Medical School. Additionally, he has been a member of the Board of Directors of Immunogen where he has served on the governance and nominating committee since November, 2011, a member of the Board of Directors of Glycomimetics since 2014, a member of the Board of Directors of aTyr Pharma and Blueprint Medicines since earlier in 2015, and he has been a member of the Board of Directors of the New England Division of the American Cancer Society since 2010. Dr. Goldberg received his A.B from Harvard College and holds a Doctor of Medicine degree from Harvard Medical School. He was on the Brigham and Women’s Hospital medical housestaff from 1981–84 and completed his hematology/oncology fellowship at Brigham and Women’s Hospital and the Dana Farber Cancer Institute. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers.